Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducted a phase 1 study to assess the safety of its combination with obinutuzumab and evaluate early efficacy in 81 patients with chronic lymphocytic leukem...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Tam, Constantine S., Quach, Hang, Nicol, Andrew, Badoux, Xavier, Rose, Hannah, Prince, H. Miles, Leahy, Michael F., Eek, Richard, Wickham, Nicholas, Patil, Sushrut S., Huang, Jane, Prathikanti, Radha, Cohen, Aileen, Elstrom, Rebecca, Reed, William, Schneider, Jingjing, Flinn, Ian W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2020
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556127/
https://ncbi.nlm.nih.gov/pubmed/33022066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002183
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller